Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Blood System Drugs >  Lusutrombopag

Lusutrombopag

Basic information Safety Supplier Related

Lusutrombopag Basic information

Product Name:
Lusutrombopag
Synonyms:
  • Lusutrombopag S-888711
  • (E)-3-[2,6-dichloro-4-[4-[3-[(S)-1-hexyloxyethyl]-2-methoxyphenyl]thiazol-2-ylcarbamoyl]phenyl]-2-methylacrylic acid
  • S 888711
  • S888711
  • S888711;S 888711
  • 2-Propenoic acid, 3-[2,6-dichloro-4-[[[4-[3-[(1S)-1-(hexyloxy)ethyl]-2-methoxyphenyl]-2-thiazolyl]amino]carbonyl]phenyl]-2-methyl-, (2E)-
  • Lusutrombopag,inhibit,Inhibitor,S888711,S 888711,Thrombopoietin Receptor
  • Rutroppa
CAS:
1110766-97-6
MF:
C29H32Cl2N2O5S
MW:
591.55
Product Categories:
  • API
Mol File:
1110766-97-6.mol
More
Less

Lusutrombopag Chemical Properties

Density 
1.299±0.06 g/cm3(Predicted)
storage temp. 
Store at 0-8 °C
solubility 
DMSO: 30 mg/ml
form 
A crystalline solid
pka
4.33±0.21(Predicted)
color 
White to off-white
InChIKey
NOZIJMHMKORZBA-KJCUYJGMSA-N
SMILES
C(O)(=O)/C(/C)=C/C1=C(Cl)C=C(C(NC2=NC(C3=CC=CC([C@@H](OCCCCCC)C)=C3OC)=CS2)=O)C=C1Cl
More
Less

Lusutrombopag Usage And Synthesis

Uses

Lusutrombopag is a newly discovered thrombopoietin receptor agonist used in the treatment of patients with chronic ITP.

Definition

ChEBI: Lusutrombopag is a member of cinnamic acids.

Mechanism of action

Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels.

Synthesis

1110768-00-7

1110766-97-6

GENERAL STEPS: In a three-necked flask equipped with a mechanical stirrer, 100 mL of tetrahydrofuran (THF) and 25.2 g (40.7 mmol) of ethyl (S,E)-3-(2,6-dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methacrylate were added. Subsequently, 1.64 g of sodium hydroxide and 100 mL of water were added and the reaction mixture was heated to 60 °C with continuous stirring for 5 hours. The progress of the reaction was monitored by thin layer chromatography (TLC) and after confirming complete consumption of the raw materials, the reaction mixture was cooled to room temperature. Most of the organic solvent was evaporated under reduced pressure and then the pH was adjusted to 2-3 by slow dropwise addition of 2 N dilute hydrochloric acid, at which point a yellow solid precipitated. The solid product was collected by filtration and washed 2-3 times with methyl tert-butyl ether to give finally (S,E)-3-(2,6-dichloro-4-((4-(3-(1-(hexyloxy)ethyl)-2-methoxyphenyl)thiazol-2-yl)carbamoyl)phenyl)-2-methylacrylic acid in white solid powder form in a yield of 23.8 g and 99% yield.

References

[1] Patent: CN106083759, 2016, A. Location in patent: Paragraph 0012

LusutrombopagSupplier

Changzhou Nuobailang Biomedical Technology Co., Ltd. Gold
Tel
13861006441
Email
780864642@qq.com
Shanghai jerryxing Biomedical Technology Co., Ltd Gold
Tel
17721492509; 17721492509
Email
643638326@qq.com
Jiangxi ravel Biotechnology Co.,Ltd Gold
Tel
400-880-2824; 13184580281
Email
hj@ruiweier.cn
Chengdu D-innovation Pharmaceutical Co.,LTD Gold
Tel
028-85929779 18881048017
Email
chenxuanruo@d-innovation.com
Tsingxin Biopharmaceutical Co., Ltd Gold
Tel
18908011947
Email
3903467217@qq.com